These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 20405170

  • 1. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal.
    Tinelli A, Malvasi A, Leo G, Vergara D, Pisanò M, Ciccarese M, Chiuri VE, Lorusso V.
    Cancer Metastasis Rev; 2010 Jun; 29(2):339-50. PubMed ID: 20405170
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT.
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
    Brunsvold AN, Wung SF, Merkle CJ.
    J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
    [Abstract] [Full Text] [Related]

  • 7. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR.
    J Clin Oncol; 2000 Nov 01; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [Abstract] [Full Text] [Related]

  • 8. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
    Maehle L, Apold J, Paulsen T, Hagen B, Løvslett K, Fiane B, Van Ghelue M, Clark N, Møller P.
    Clin Cancer Res; 2008 Nov 15; 14(22):7569-73. PubMed ID: 19010876
    [Abstract] [Full Text] [Related]

  • 9. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R.
    Cancer; 2005 Dec 15; 104(12):2807-16. PubMed ID: 16284991
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC, Durocher F, Smith P, Simard J, Easton DF, INHERIT BRCAs program members.
    Breast Cancer Res; 2006 Dec 15; 8(1):R3. PubMed ID: 16417652
    [Abstract] [Full Text] [Related]

  • 17. [In cases of familial ovarian cancer, always consider the risk of breast cancer].
    Kets CM, Niermeijer MF, Massuger LF, Hoogerbrugge N.
    Ned Tijdschr Geneeskd; 2004 Aug 28; 148(35):1709-11. PubMed ID: 15468897
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.
    J Clin Oncol; 2003 May 01; 21(9):1675-81. PubMed ID: 12721241
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.